Indian Priority Pathogen List (IPPL): WHO & DBT

Indian Priority Pathogen List (IPPL): WHO & DBT

The objectives of the IPPL are to
• guide the prioritization of research on AMR, including incentives and funding;
• help align R&D priorities with Indian public health needs; and
• support India’s leadership in containment of antibiotic resistant bacteria

The IPPL shall be useful for policy initiatives to incentivise basic science and advanced R&D by
both public funding agencies and the private sector investing in new antibiotics.

CRITICAL PRIORITY

Enterobacteriaceae
(Klebsiella pneumoniae and Escherichia coli)

Carbapenem – R
Tigecycline – R
Colistin – R
Non-fermenting bacteria
(Acinetobacter baumannii and Pseudomonas aeruginosa)

Carbapenem – R
Colistin – R


HIGH PRIORITY

Staphylococcus aureus
MRSA, hVISA
Daptomycin – NS
Linezolid – R
Enterococcus species
Vancomycin – R
Linezolid – R
Daptomycin – NS
Salmonella species
(Typhoidal and Non-typhoidal)

Azithromycin – NS
Third generation cephalosporins – NS
Carbapenem – NS

MEDIUM PRIORITY

Streptococcus pneumoniae
Cephalosporin – R
Fluoroquinolones – R
Linezolid – R
Staphylococcus, coagulase-negative
Vancomycin – R
Linezolid – R
Shigella species
Third generation cephalosporins – R
Azithromycin – R
Haemophilus influenzae
Third generation cephalosporin – NS
Carbapenem – NS
Neisseria meningitidis
Fluoroquinolones – NS
Third generation cephalosporins – NS


The following steps were followed for developing the IPPL:

  1. Desk review of biomedical literature on key antibiotic resistant bacteria in the Indian
    context;
  2. Analysis of available data and information on bacterial drug resistance mechanisms;
  3. Prepare draft list of prioritized antibiotic-resistant bacteria and key resistance
    mechanisms; and
  4. Review and finalization of the list of top-10 bacterial drug-resistant pathogens

Suggested readings:

IPC Nagpur

Related Blogs